E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
proven or suspected bacterial meningitis in neonates and infants up to 90 days of age |
|
E.1.1.1 | Medical condition in easily understood language |
meningitis in neonates and infants |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10004049 |
E.1.2 | Term | Bacterial meningitis |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
to study the pharmacokinetics (plasma and cerebrospinal fluid) of meropenem in infants ≤ 90 days of postnatal age with probable or confirmed bacterial meningitis and to characterize the safety profile of meropenem in the treatment of infants ≤ 90 days of postnatal age with probable or confirmed bacterial meningitis. |
|
E.2.2 | Secondary objectives of the trial |
To describe the efficacy of meropenem on day 3, at end of allocated treatment (EOAT), at test of cure (TOC) and at follow up (FU).
To evaluate survival at FU
To evaluate further episodes of meningitis (relapse or new infection) occurring between TOC and FU visits
To define the organisms causing neonatal meningitis
To describe the antibacterial susceptibility of meningitis-causing organisms and to describe the clinical and microbiological response according to this
To evaluate mucosal colonization by resistant organisms before and after treatment with meropenem
To evaluate bacterial eradication
To evaluate functional genetic parameters that may affect response to therapy |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Pharmacokinetics of meropenem in neonates infants ≤ 90 days of
postnatal age with bacterial meningitis. 08.07.2011/ version 2.0
Microbiology substudy: gut colonisation with resistant microorganisms in neonates and infants treated with meropenem for bacterial meningitis. 08.07.2011/ version 2.0
Genetic determinants of susceptibility to meningitis and to differential responses to Meropenem. 08.07.2011/ version 2.0 |
|
E.3 | Principal inclusion criteria |
Informed consent form signed by the parents/carers
Chronological age below 90 days inclusive
The presence of: clinical signs consistent with bacterial meningitis (clinical signs of meningitis are: fever or hypothermia or temperature instability PLUS 1 or more neurological findings e.g. coma, seizures, neck stiffness, apnoea, bulging fontanelle) OR CSF pleocytosis (≥ 20 cells / mm3 OR a positive Gram stain of CSF. |
|
E.4 | Principal exclusion criteria |
Presence of a CSF device
Proven viral or fungal meningitis
Severe congenital malformations if the infant is not to expect to survive for more than 3 months
Other situations where the treating physician considers a different empiric antibiotic regimen necessary
Known intolerance or contraindication to the study medication
Participation in any other clinical study of an investigational medicinal product
Renal failure and requirement of haemofiltration or peritoneal dialysis
Meningitis with an organism known to be resistant to meropenem |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The PK of meropenem (plasma and CSF) in infants ≤ 90 days of age diagnosed with probable and confirmed BM
Adverse events experienced by infants receiving meropenem. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Meropenem PK will be studied in steady state on the 3rd study day.
Clinical and biological adverse events will be recorded until follow-up visit on Day 45 +/- 3 |
|
E.5.2 | Secondary end point(s) |
A favourable outcome defined at Test of Cure visit (TOC), 2 days after EOAT as an infant fulfilling the following criteria: Alive with clinical and bacteriological resolution of the abnormalities that defined BM at entry and no occurrence of any new clinical or laboratory abnormalities requiring a new course of antibiotic therapy and no modification of the initial meropenem therapy (for more than 24 hours).
Clinical, biological and microbiological response at day 3, at EOAT, at TOC and at FU;
Survival at FU visit;
Auditory function as assessed by brain-stem auditory evoked potentials between COT and FU visits;
Neurological evaluation as assessed by cerebral ultrasound (and if persistently abnormal, by MRI or CT) at any time up until the FU visit;
The organisms causing neonatal meningitis;
The antibiotic susceptibility of bacteria causing BM;
Mucosal colonisation with antibiotic resistant bacteria or fungi at enrolment, EOAT and FU / discharge (whichever is earlier)
Genetic parameters that can affect response to therapy |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
End of allocated treatment (EOAT) -- the point in time when allocated therapy for meningitis is stopped, that means the last day of allocated treatment.
TOC visit is performed 2 ± 1 days after EOAT
Follow up (FU) visit is performed at Day 45 ± 3. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 61 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
IDMC performs an interim review of the trial's progress including
updated figures on recruitment, data quality, and main safety outcomes. Based on its review, the IDMC will provide within 15 days after each of its meetings a written report with recommendations to the sponsor regarding study modification, continuation or termination. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 0 |